Ketorolac tromethamine use in a university-based emergency department
- PMID: 7600400
- DOI: 10.1111/j.1553-2712.1994.tb02548.x
Ketorolac tromethamine use in a university-based emergency department
Abstract
Objective: To assess the use of parenteral ketorolac tromethamine (KT) in the emergency department (ED).
Methods: During a six-month period, KT was administered in an uncontrolled, nonblinded fashion to a series of ED patients experiencing acute pain. The patients rated pain on a previously validated visual analog pain scale before receiving KT. They repeated this procedure one hour after KT administration, prior to additional analgesia, or preceding release, whichever came first. Analgesic response was assessed by comparing pretreatment and posttreatment pain scores for the entire study population by the Wilcoxon rank sum test. Possible effects of specific variables (patient age, gender, race, indication for KT, route, dose, previous use of NSAIDs, and concurrent administration of muscle relaxants) were assessed using the Kruskal-Wallis test.
Results: Of the 445 patients enrolled, 375 (84%) reported pain relief with KT, only seven (2%) worsened, and the remainder (14%) reported no change. Overall pain reduction was 37.6 +/- 27.2 (SD) mm (100-mm scale) for the entire study population. The pain scores obtained after KT administration were significantly lower than those obtained prior to KT administration (p < 0.001). The only variable that significantly influenced pain score reduction was indication for KT (p = 0.001). Nephrolithiasis and toothache patients had the largest mean reductions in pain. No significant side effect was reported.
Conclusion: Parenteral KT is a useful and safe analgesic for ED patients. The agent generally provides analgesia and is particularly promising for patients with nephrolithiasis or toothache.
Similar articles
-
Utilization of ketorolac tromethamine for control of severe odontogenic pain.J Endod. 1994 Sep;20(9):457-9. doi: 10.1016/S0099-2399(06)80038-5. J Endod. 1994. PMID: 7996118 Clinical Trial.
-
Ketorolac vs meperidine for the management of pain in the emergency department.Acad Emerg Med. 1994 Nov-Dec;1(6):544-9. doi: 10.1111/j.1553-2712.1994.tb02550.x. Acad Emerg Med. 1994. PMID: 7600401 Clinical Trial.
-
The efficacy of sublingual hyoscyamine sulfate and intravenous ketorolac tromethamine in the relief of ureteral colic.Am J Emerg Med. 1998 Oct;16(6):557-9. doi: 10.1016/s0735-6757(98)90217-0. Am J Emerg Med. 1998. PMID: 9786536 Clinical Trial.
-
Ketorolac tromethamine: an oral/injectable nonsteroidal anti-inflammatory for postoperative pain control.J Oral Maxillofac Surg. 1992 Dec;50(12):1310-3. doi: 10.1016/0278-2391(92)90233-p. J Oral Maxillofac Surg. 1992. PMID: 1447612 Review.
-
Ketorolac, an injectable nonnarcotic analgesic.Clin Pharm. 1990 Dec;9(12):921-35. Clin Pharm. 1990. PMID: 2292174 Review.
Cited by
-
Formulation of controlled-release baclofen matrix tablets: influence of some hydrophilic polymers on the release rate and in vitro evaluation.AAPS PharmSciTech. 2007 Nov 30;8(4):E100. doi: 10.1208/pt0804100. AAPS PharmSciTech. 2007. PMID: 18181521 Free PMC article.
-
Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.Drugs. 1997 Jan;53(1):139-88. doi: 10.2165/00003495-199753010-00012. Drugs. 1997. PMID: 9010653 Review.
-
Cost effectiveness analysis of intravenous ketorolac and morphine for treating pain after limb injury: double blind randomised controlled trial.BMJ. 2000 Nov 18;321(7271):1247-51. doi: 10.1136/bmj.321.7271.1247. BMJ. 2000. PMID: 11082083 Free PMC article. Clinical Trial.
-
Investigating the antimicrobial, antioxidant and cytotoxic activities of the biological synthesized glutathione selenium nano-incorporation.Biometals. 2021 Aug;34(4):815-829. doi: 10.1007/s10534-021-00309-w. Epub 2021 Apr 24. Biometals. 2021. PMID: 33895912
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical